Patiromer (Veltassa®)
Patiromer (Veltassa®) is indicated for the treatment of hyperkalaemia in adults.
NCPE Assessment Process | Complete |
Rapid review received | 11/10/2017 |
Rapid review completed | 17/11/2017 |
Rapid Review outcome | Full pharmacoeconomic assessment recommended |
Full pharmacoeconomic assessment commissioned by HSE | 20/11/2017 |
Pre-submission consultation with Applicant | 16/01/2018 |
Submission received from Applicant | 13/04/2018 |
Preliminary review sent to Applicant | 15/10/2018 |
NCPE assessment re-commenced | 13/11/2018 |
Factual accuracy sent to Applicant | 21/01/2019 |
NCPE assessment re-commenced | 04/02/2019 |
NCPE assessment completed | 13/02/2019 |
NCPE assessment outcome | The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
Re-submission of HTA
NCPE Assessment Process | Ongoing |
Re-submission of HTA commissioned by the HSE | 30/06/2020 |
Pre-submission consultation with Applicant | 23/11/2020 |
Current status | Awaiting HTA submission from Applicant |